Drug Database
Back to search

Netherlands· NL-f845a55f5c23

ROMVIMZA 30 mg harde capsules

A vimseltinib product containing vimseltinib 2-water, registered in Netherlands by Deciphera Pharmaceuticals (Netherlands) B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC L01EX29

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedROMVIMZA 30 mg harde capsulesATCL01EX29REGISTER NO.NL-f845a55f5c23PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about vimseltinib 2-waterAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Vimseltinib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EX29 (vimseltinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search vimseltinib products by name

Vimseltinib · ATC L01EX29

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Spainprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
VIMSELTINIB 2-WATER
Manufacturer
Deciphera Pharmaceuticals (Netherlands) B.V.
Country
Netherlands (NL)
ATC code
L01EX29
ATC class
Vimseltinib
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1968

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vimseltinib in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vimseltinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Romvimza
  • Liechtenstein · Romvimza
  • Norway · Romvimza

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/77062224-d1aa-4967-816a-ff820e5bbc03
GET /v1/drugs/77062224-d1aa-4967-816a-ff820e5bbc03?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/romvimza-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Vimseltinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133807",
  "excipients": [
    "BRILJANTBLAUW FCF (E 133)",
    "CROSPOVIDON (E 1202)",
    "ERYTHROSINE (E 127)",
    "GELATINE (E 441)",
    "IJZEROXIDE ZWART (E 172)",
    "KALIUMHYDROXIDE (E 525)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "VIMSELTINIB 2-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/09/17",
  "procedure_number": "EMEA/H/C/006363",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1968",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about vimseltinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console